History at Codexis

Our History

2023

Positive initial data in P1 trial of CDX-7108 for EPI

Unveiled ECO Synthesis™ technology for RNAi therapeutics production at TIDES USA

2022

CDX-6512 Received Orphan Drug Designation For Homocystinuria

seqWell - Partnered in the Genomics and NGS Market

2021

Launched Codex® HiTemp Reverse Transcriptase

2020

Molecular Assemblies – Partnered On Enzymatic DNA Synthesis

Launched Codex® HiFi DNA Polymerase & Codex® HiCap RNA Polymerase

Takeda – Gene Therapy Collaboration And License Agreement

Extended Biotherapeutics Partnering Deal With Nestlé Health Science

2019

Evo T4 DNA Ligase For Next Gen Sequencing Licensed To Roche

Novartis CodeEvolver® Platform License

First Successful Clinical Trial Completed: CDX-6114 For PKU

2017

First Partnering Deal In Biotherapeutics With Nestlé Health Science

2015

Merck – CodeEvolver® Platform License

2014

GlaxoSmithKline – CodeEvolver® Platform License

2012

Merck – FDA Approval For Sitagliptin API Process Using CDX-017

2010

Codexis IPO On Nasdaq

2002

Codexis Spun-Out From Maxygen